IMMU - Immunomedics, Inc.
| Previous Close | 18.98 |
| Open | 18.93 |
| Bid | 0.00 x 300 |
| Ask | 24.05 x 1000 |
| Day's Range | 17.54 - 19.23 |
| 52 Week Range | 11.82 - 27.33 |
| Volume | 2,313,375 |
| Avg. Volume | 1,933,535 |
| Market Cap | 3.339B |
| Beta (3Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.29 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.86 |
- GlobeNewswire•4 days ago
Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan
Updated Phase 2 Results in Metastatic Triple-Negative Breast Cancer to be Presented at The 2018 San Antonio Breast Cancer Symposium (SABCS) Continue to Show Meaningful Clinical.
- InvestorPlace•6 days ago
8 Companies That Could Disappear in 2019
With that as the backdrop, here are the eight major companies most likely to pull a vanishing act in 2019. Between cheaper options online and the move from venues like Bed Bath & Beyond Inc. (NASDAQ:BBBY) and home improvement retailers like Home Depot Inc (NYSE:HD) to get deeper into the organizational market, The Container Stores simply became less of a draw.
- CNBC•6 days ago
Cramer's lightning round: My playbook for Okta's earnings report
Jim Cramer races through his answers to callers' stock questions, including one on a software play ahead of the company's earnings report.
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of IMMU earnings conference call or presentation 7-Nov-18 10:00pm GMT
Q1 2019 Immunomedics Inc Earnings Call
- ACCESSWIRE•7 days ago
Today's Research Reports on Trending Tickers: Immunomedics and Amarin
A “trade war truce” was expected to come from the dinner between President Trump and Chinese President Xi Jinping over the weekend and that is what exactly happened. China and the United States agreed to a ceasefire in their bitter trade war on Saturday, including no escalated tariffs in Jan. Trump will leave tariffs on $200 billion worth of Chinese imports at 10 percent at the beginning of the new year. The Nasdaq Composite Index climbed 0.79 percent to close at 7,330.54.
- Zacks•10 days ago
Why Immunomedics (IMMU) Could Be Positioned for a Slump
Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- GlobeNewswire•13 days ago
New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Market Realist•14 days agoMirati Therapeutics Stock Has Delivered Solid Growth in 2018
Mirati Therapeutics hit a 52-week high of $65.35 on July 31. In November, Mirati Therapeutics presented the preliminary biomarker data from the ongoing Phase 2 clinical trial of its sitravatinib and Bristol-Myers Squibb’s Opdivo combination therapy. Mirati Therapeutics is conducting the Phase 2 trial of the sitravatinib and Opdivo combination therapy for the evaluation of its safety and efficacy in the treatment of non-small cell lung cancer.
- Zacks•21 days ago
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
- Motley Fool•last month
Here's Why Immunomedics Fell as Much as 10.8% Today
A handful of updates heading into a critical regulatory review date had investors reconsidering a healthy market cap.
- GlobeNewswire•last month
Immunomedics Announces Presentation at Upcoming Healthcare Conferences
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in fireside chat at the following healthcare conferences. Live audio webcast will be accessible from the Company’s website at https://immunomedics.com/investors/.
- Zacks•last month
Immunomedics (IMMU) Reports Q1 Loss, Misses Revenue Estimates
Immunomedics (IMMU) delivered earnings and revenue surprises of -25.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Immunomedics: Fiscal 1Q Earnings Snapshot
On a per-share basis, the Morris Plains, New Jersey-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring gains, were 35 cents per share. The results missed Wall Street expectations. ...
- GlobeNewswire•last month
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
Strategic Manufacturing Partnership Entered into with Samsung BioLogics to Provide Anticipated Long-Term Supply of Sacituzumab Govitecan Commercial Launch Preparations Nearing.
- GlobeNewswire•last month
Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced its current clinical collaboration with AstraZeneca (AZN) and MedImmune for the development of Imfinzi® (durvalumab) and sacituzumab govitecan combination therapy has been broadened to include second-line metastatic non-small cell lung cancer (NSCLC). “Sacituzumab govitecan has shown very encouraging single-agent activity in NSCLC patients who have failed multiple lines of therapy.
- GlobeNewswire•last month
Immunomedics to Report First Quarter Fiscal 2019 Results and Host Conference Call and Webcast on November 7, 2018
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, November 7, 2018 at 5:00 p.m. Eastern Time to discuss first quarter fiscal 2019 financial results and provide a corporate update. To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 1568527. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/.
- Zacks•2 months ago
Immunomedics (IMMU) Looks Good: Stock Adds 5.5% in Session
Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Immunomedics and GlaxoSmithKline
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Immunomedics and FibroGen
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Major U.S. equities finished moderately lower on Wednesday with the Dow Jones dropping over 300 points after minutes from the Federal Reserve September’s ...
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Amarin and Immunomedics
NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. S&P 500 Index decreased 2.06 percent to close at 2,728.37 and the Nasdaq Composite Index closed down 1.25 percent to close at 7,329.06. The market losses are “a reaction from investors finally realizing we are in a higher interest-rate environment, and given the elevated level of stocks, market participants were likely looking for a reason to sell,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of IMMU earnings conference call or presentation 23-Aug-18 9:00pm GMT
Q4 2018 Immunomedics Inc Earnings Call
- Zacks•2 months ago
Implied Volatility Surging for Immunomedics (IMMU) Stock Options
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Market Realist•2 months agoHere’s What’s Driving Investor Interest in Immunomedics
Wall Street Calls These Biotech Stocks 'Strong Buys' in SeptemberImmunomedics’ target price
- GlobeNewswire•3 months ago
Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership
Immunomedics, Inc., (IMMU) and Samsung BioLogics Co., Ltd. today announced the companies have entered into a long-term manufacturing partnership agreement under which Samsung will manufacture Immunomedics’ proprietary humanized antibody, hRS7, at its manufacturing facilities in Incheon, South Korea. “This agreement is an important part of our overall strategy to further enhance our supply chain and continue to improve our cost-structure,” said Dr. Morris Rosenberg, Chief Technology Officer of Immunomedics.
